C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64. - PowerPoint PPT Presentation

Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Features C-SCAPE Trial  Design : Open-label, phase 2 trial to evaluate the efficacy and safety of elbasvir + grazoprevir + ribavirin versus elbasvir + grazoprevir versus grazoprevir + ribavirin in non-cirrhotic, treatment-naïve patients with GT 2, 4, 5, or 6 chronic hepatitis C infection  Entry Criteria - Chronic HCV GT2 (n = 60), GT4 (n = 20), GT5 (n = 8), or GT6 (n = 10) - Age 18 years or older - No prior HCV treatment - HCV RNA ≥10,000 IU/mL - No evidence of cirrhosis  Primary End-Point : SVR12 Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Study Design for GT 1 Week 0 12 24 n = 30 EBR-GZR + RBV SVR12 GT 2 Non-cirrhotic GZR + RBV SVR12 n = 30 n = 19 EBR-GZR + RBV SVR12 GT 4, 5, or 6 Non-cirrhotic n = 19 EBR-GZR SVR12 Abbreviations : EBR = Elbasvir; GZR = Grazoprevir; RBV = ribavirin Drug Dosing Elbasvir (50 mg) once daily Grazoprevir (100 mg) once daily Ribavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Baseline Characteristics Genotype 2 Genotype 4, 5, 6 Baseline EBR + GZR + RBV GZR + RBV EBR + GZR + RBV EBR-GZR Characteristic (n = 30) (n = 30) (n = 19) (n = 19) Mean age, y (range) 47.3 48.3 52.2 52.8 Male sex, % 63.3 56.7 42.1 63.2 Race, % White 100 86.7 73.7 68.4 Other 0 13.3 26.3 31.6 HCV Genotype, n 2 30 26 0 0 4 0 0 10 10 5 0 0 4 4 6 0 0 4 4 1 -- 4 -- -- HCV RNA ≤ 2 million 36.7 36.7 57.9 36.8 >2 million 63.3 63.3 42.1 63.2 *Excluded from modified intent-to-treat analysis due to discordant genotype Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5, or 6 C-SCAPE Study: Results C-SCAPE: SVR12 by Genotype and Regimen EBR + GZR + RBV x 12 weeks EBR + GZR + RBV x 12 weeks GZR + RBV x 12 weeks EBR + GZR x 12 weeks 100 100 100 Patients (%) with SVR 12 90 80 80 75 75 73 60 40 20 25 24/30 19/26 10/10 9/10 4/4 1/4 3/4 3/4 0 GT2 GT4 GT5 GT6 Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Conclusions Conclusions : “The se data support the inclusion of participants with genotype 4 or 6 infection in the elbasvir-grazoprevir phase 3 studies. Elbasvir-grazoprevir ± ribavirin was unsatisfactory for participants with genotype 2 or 5 infection. ” Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64. - PowerPoint PPT Presentation

Phase 2 Treatment Nave Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Nave HCV GT 2, 4, 5, or 6 C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64. Elbasvir + Grazoprevir +/- RBV in Treatment-Nave GT 2, 4, 5 or 6 C-SCAPE

SCAPE: Shape Completion SCAPE: Shape Completion and Animation of People and Animation of People

E In This Issue scape From the Island of Escape From the Island of the One-Way Termination:

WERE The Scape pe C Cons nstruc uct information evening for Reside dent nts affected by

National Civil Engineering & Infrastructure Framework Roger Steeper Framework Manager

National Civil Engineering & Infrastructure Framework London 8 th December 2017 Matt

Le Legi gislativ slative e La Land ndscape scape

ECOLOGY + ENGINEERING+ ENGAGEMENT Pippa Brashear SCAPE Landscape Architecture APRIL 23, 2018

of India | Iran | Nepal | Nigeria | Oman | Qatar CITY SCAPE www.beyondsquarefeet.com 2

Courtesy: SCAPE / Landscape Architecture Rebuild by Design Team Courtesy: SCAPE / Landscape

of DCM Road, Kota India | Iran | Nepal | Nigeria | Oman | Qatar CITY SCAPE

validation tool Alecs Geuder SCAPE Information Day British Library, UK, 14 th July 2014

SCAPE JOYCE YE SITE:MOTAT NOMINATED AREA:CONTEMPORARY ART HISTORY OF MOTAT MURAL &

F INANCIAL PRE PARE DNE SS AND E ST AT E PL ANNING Wha ts in YOUR wa lle t? No

Background Cooper, Julia McLeod and colleagues, set up Tayside Centre for Counselling 1

Goals Progress Vision Success In 2003 concerned property owners formed the 1 st CID in Gwinnett

WEB ARCHIVING @ LIP6 S TPHANE G ANARSKI Z. P EHLIVAN , M. C ORD , M. B EN -S AAD , A. S ANOJA

175,000 Australians live with chronic HCV infection (December 2017) Stigma Symptoms Uptake of

Awareness as a policy lever Webinar 3 19.00 20:00 BST 4 April 2016 #ToolsForChange WELCOME

Lung Cancer Update From ASCO Edward Garon, M.D. Assistant Professor Division of

Caveats of Randomized Clinical Trials for Economic Analysis Suzanne Wait Ph.D. Associate

A D D I T I O N A L D U E D I L I G E N C E M AT E R I A L S I P O V E RV I E W O C TO B E R 2

C O R P O R AT E P R E S E N TAT I O N F E B R UA R Y 2 0 1 8 CAUTIONARY STATEMENT This

On the Evaluation of Outlier Detection: Measures, Datasets, and an Empirical Study Continued

Overview In this tutorial, we will learn how to log into the EE server, Bender. Then, we will

C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64. - PowerPoint PPT Presentation

Phase 2 Treatment Nave Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Nave HCV GT 2, 4, 5, or 6 C-SCAPE Source: Brown A, et al. J Viral Hepat. 2018;25:457-64. Elbasvir + Grazoprevir +/- RBV in Treatment-Nave GT 2, 4, 5 or 6 C-SCAPE

SCAPE: Shape Completion SCAPE: Shape Completion and Animation of People and Animation of People

E In This Issue scape From the Island of Escape From the Island of the One-Way Termination:

WERE The Scape pe C Cons nstruc uct information evening for Reside dent nts affected by

National Civil Engineering &amp; Infrastructure Framework Roger Steeper Framework Manager

National Civil Engineering &amp; Infrastructure Framework London 8 th December 2017 Matt

Le Legi gislativ slative e La Land ndscape scape

ECOLOGY + ENGINEERING+ ENGAGEMENT Pippa Brashear SCAPE Landscape Architecture APRIL 23, 2018

of India | Iran | Nepal | Nigeria | Oman | Qatar CITY SCAPE www.beyondsquarefeet.com 2

Courtesy: SCAPE / Landscape Architecture Rebuild by Design Team Courtesy: SCAPE / Landscape

of DCM Road, Kota India | Iran | Nepal | Nigeria | Oman | Qatar CITY SCAPE

validation tool Alecs Geuder SCAPE Information Day British Library, UK, 14 th July 2014

SCAPE JOYCE YE SITE:MOTAT NOMINATED AREA:CONTEMPORARY ART HISTORY OF MOTAT MURAL &amp;

F INANCIAL PRE PARE DNE SS AND E ST AT E PL ANNING Wha ts in YOUR wa lle t? No

Background Cooper, Julia McLeod and colleagues, set up Tayside Centre for Counselling 1

Goals Progress Vision Success In 2003 concerned property owners formed the 1 st CID in Gwinnett

WEB ARCHIVING @ LIP6 S TPHANE G ANARSKI Z. P EHLIVAN , M. C ORD , M. B EN -S AAD , A. S ANOJA

175,000 Australians live with chronic HCV infection (December 2017) Stigma Symptoms Uptake of

Awareness as a policy lever Webinar 3 19.00 20:00 BST 4 April 2016 #ToolsForChange WELCOME

Lung Cancer Update From ASCO Edward Garon, M.D. Assistant Professor Division of

Caveats of Randomized Clinical Trials for Economic Analysis Suzanne Wait Ph.D. Associate

A D D I T I O N A L D U E D I L I G E N C E M AT E R I A L S I P O V E RV I E W O C TO B E R 2

C O R P O R AT E P R E S E N TAT I O N F E B R UA R Y 2 0 1 8 CAUTIONARY STATEMENT This

On the Evaluation of Outlier Detection: Measures, Datasets, and an Empirical Study Continued

Overview In this tutorial, we will learn how to log into the EE server, Bender. Then, we will

National Civil Engineering & Infrastructure Framework Roger Steeper Framework Manager

National Civil Engineering & Infrastructure Framework London 8 th December 2017 Matt

SCAPE JOYCE YE SITE:MOTAT NOMINATED AREA:CONTEMPORARY ART HISTORY OF MOTAT MURAL &